| __timestamp | United Therapeutics Corporation | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 381287000 | 305409000 |
| Thursday, January 1, 2015 | 452612000 | 377080000 |
| Friday, January 1, 2016 | 316800000 | 432829000 |
| Sunday, January 1, 2017 | 330100000 | 496079000 |
| Monday, January 1, 2018 | 265800000 | 557616000 |
| Tuesday, January 1, 2019 | 336200000 | 658498000 |
| Wednesday, January 1, 2020 | 423900000 | 770456000 |
| Friday, January 1, 2021 | 467000000 | 840100000 |
| Saturday, January 1, 2022 | 487000000 | 944700000 |
| Sunday, January 1, 2023 | 477100000 | 1136600000 |
| Monday, January 1, 2024 | 1464300000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation have showcased contrasting strategies in optimizing these costs. From 2014 to 2023, Vertex Pharmaceuticals saw a significant increase in SG&A expenses, rising by approximately 272%, from $305 million to over $1.1 billion. In contrast, United Therapeutics maintained a more stable trajectory, with a modest 25% increase, from $381 million to $477 million.
This data highlights Vertex's aggressive expansion and investment in administrative capabilities, while United Therapeutics appears to focus on cost efficiency. As the biotech industry continues to evolve, these strategies will play a pivotal role in shaping the financial health and competitive edge of these companies.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or United Therapeutics Corporation
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.
Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
Teva Pharmaceutical Industries Limited and United Therapeutics Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Summit Therapeutics Inc.
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Perrigo Company plc
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Celldex Therapeutics, Inc.